Meta-Analysis of Independent Research Supports Potential for Oral Salmon Calcitonin Using Emisphere Technologies, Inc.'s Eligen(R) Technology as Therapeutic Option for Persistent Musculoskeletal Pain

CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB: EMIS) today announced a meta-analysis published in the December 2009 edition of Rheumatology Reports examining independent evidence of the analgesic action of the hormone calcitonin. This publication restates the potential of calcitonin in filling a significant unmet need for alternative treatments for persistent musculoskeletal pain.